{"id":"NCT02475629","sponsor":"TaiMed Biologics Inc.","briefTitle":"Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV","officialTitle":"A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2016-10","completion":"2016-12","firstPosted":"2015-06-19","resultsPosted":"2020-03-19","lastUpdate":"2020-03-19"},"enrollment":40,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV"],"interventions":[{"type":"BIOLOGICAL","name":"ibalizumab","otherNames":["TNX-355","Hu1A8"]},{"type":"DRUG","name":"Optimized Background Regimen (OBR)","otherNames":[]}],"arms":[{"label":"Open-Label Ibalizumab plus OBR","type":"EXPERIMENTAL"}],"summary":"This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.","primaryOutcome":{"measure":"Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF","timeFrame":"Day 14","effectByArm":[{"arm":"Open-Label Ibalizumab Plus OBR","deltaMin":0.825,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":12},"locations":{"siteCount":30,"countries":["United States","Puerto Rico","Taiwan"]},"refs":{"pmids":["30110589"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":40},"commonTop":["Diarrhoea","Nausea","Fatigue","Rash","Dizziness"]}}